Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wheeler

Showing results (1121-1130 of 1,154) with videos related to

Pageof 116
Sort By:
Cell Death & Disease|May 30, 2024
Biallelic variants in CSMD1 are implicated in a neurodevelopmental disorder with intellectual disability and variable cortical malformationsElizabeth A Werren, Emily R Peirent, Henna Jantti, et al.
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
Journal of the National Cancer Institute|July 12, 2019
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR ConsortiumWilliam E Barlow, Elisabeth F Beaber, Berta M Geller, et al.
Arxiv|January 7, 2025
GREGoR: Accelerating Genomics for Rare DiseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Osteoarthritis and Cartilage|December 15, 2010
Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritisH J M Kerkhof, M Doherty, N K Arden, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 116

Showing results (1121-1130 of 1,154) with videos related to

Sort By:
Pageof 116
Cell Death & Disease|May 30, 2024
Biallelic variants in CSMD1 are implicated in a neurodevelopmental disorder with intellectual disability and variable cortical malformationsElizabeth A Werren, Emily R Peirent, Henna Jantti, et al.
Plos One|November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA studyUnnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
The Lancet. Oncology|November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialMatti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Obstetrics and Gynecology|July 12, 2018
Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of AgeSuzanne M Garland, Elmar A Joura, Kevin A Ault, et al.
The Lancet. Oncology|May 3, 2005
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialLuisa L Villa, Ronaldo L R Costa, Carlos A Petta, et al.
Clinical and Vaccine Immunology : CVI|December 26, 2014
Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNAFrank Struyf, Brigitte Colau, Cosette M Wheeler, et al.
Journal of the National Cancer Institute|July 12, 2019
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR ConsortiumWilliam E Barlow, Elisabeth F Beaber, Berta M Geller, et al.
Arxiv|January 7, 2025
GREGoR: Accelerating Genomics for Rare DiseasesMoez Dawood, Ben Heavner, Marsha M Wheeler, et al.
Osteoarthritis and Cartilage|December 15, 2010
Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritisH J M Kerkhof, M Doherty, N K Arden, et al.
Lancet (London, England)|December 8, 2009
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years, B Romanowski, P Colares de Borba, et al.
Pageof 116